Century Therapeutics, Inc. (IPSC) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

47NeutralDD: Sep 11, 2026Analyst: 61

paidPrice at analysis date

USD 2.00 (11/09/2026)

domainMkt cap

$362M

pie_chartShares

181,075,321

candlestick_chart52W

$0.435-$3.04

trending_downShort interest

29.0%

INFONASDAQHealth CareFounded 2018

Verdict: Moderately Attractive — Binary, pre-IND biotech

Clinical-stage iPSC cell-therapy platform that lost its only pharma validation (Bristol-Myers Squibb terminated its ~$3B+ biobucks oncology collaboration effective March 12, 2025) and pivoted its lead program to type 1 diabetes (CNTY-813, islet cell replacement). Cash runway into 1Q 2029 genuinely covers both near-term catalysts, but roughly 95M new shares plus 58.7M warrants issued since January 2026 have already diluted holders by ~2x, and the FY2025 "revenue" spike is a one-time accounting artifact of the BMS termination, not organic growth. The Q4 2026 IND filing for CNTY-813 is the binary event the entire thesis hinges on.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated September 11, 2026

Century Therapeutics, Inc. (IPSC)

Cell Therapy / Biotechnology · NASDAQ · Philadelphia, PA

"Solid cash runway and a real IND catalyst, undercut by heavy dilution and a lost pharma partner — the risk/reward is balanced, not compelling."

Pre-revenue Cash to 1Q29 Binary IND catalyst Q4'26 No debt 29% short interest

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — Probability-Weighted rNPV (pipeline) + Net Cash, dilution-adjusted

Fair value base case

USD 2.29

Range: USD 0.40-USD 7.00

Price at analysis date: USD 2.00 (11/09/2026)

Base upside/downside: +15%

rNPV sum-of-the-parts for the two wholly-owned clinical programs, with peak sales and launch multiples anchored to comparable curative cell/gene therapies and disclosed explicitly; net cash from the June 30, 2026 balance sheet; an explicit −15% dilution haircut for the 58.7M warrant shares and $131.6M residual ATM capacity. SENSITIVITY: doubling the launch multiples (3.5x/3.0x → 7x/6x) would raise pre-dilution pipeline value from ~$1.90 to ~$3.80/sh — a swing of roughly +75% in the base case, well above the ±30% stability threshold, so treat the $2.29 base case as the center of a wide distribution, not a precise point estimate. ⚠️ Not investment advice.

Component	Assumption	USD/share
CNTY-813 (T1D islet replacement) — rNPV	8% PoS (pre-IND) × $1.8B risk peak sales × 3.5x launch multiple, PV at 13% WACC over 6 yrs to launch	+1.34
CNTY-308 (CD19 CAR-iT, B-cell autoimmune) — rNPV	10% PoS (pre-Phase 1) × $0.8B peak sales × 3.0x launch multiple, PV at 13% WACC over 7 yrs	+0.56
Net cash position	$197.2M cash & investments (6/30/26) − $54.7M total liabilities, / 181.1M shares	+0.79
Expected dilution (warrants + ATM)	58.7M warrant shares (+32% vs. current count) + $131.6M ATM shelf remaining; −15% haircut on pipeline + cash sum	−0.40
FV base case	Exact sum of rows above (1.34 + 0.56 + 0.79 − 0.40)	≈ $2.29

Bull

$5.00–$7.00

Probability: 20%

CNTY-813 IND clears cleanly in Q4 2026, a new pharma partner signs before Phase 1/2 data (non-dilutive capital, de-risking), and the market re-prices approval odds toward sell-side assumptions (~20% PoS, $3.4B peak sales).

Base

$1.70–$3.00

Probability: 45%

IND filed roughly on time with standard back-and-forth, incremental clinical progress on both programs, continued reliance on the ATM and warrant exercises to fund the path to 1Q29 without a new partner.

Bear

$0.40–$1.00

Probability: 35%

IND delay, clinical hold, or a CRL-equivalent setback; warrants and ATM are used aggressively to plug the gap, and the market discounts the pipeline to near the net-cash floor ahead of 2H 2027 data.

Methodology: rNPV sum-of-the-parts for the two wholly-owned clinical programs, with peak sales and launch multiples anchored to comparable curative cell/gene therapies and disclosed explicitly; net cash from the June 30, 2026 balance sheet; an explicit −15% dilution haircut for the 58.7M warrant shares and $131.6M residual ATM capacity. SENSITIVITY: doubling the launch multiples (3.5x/3.0x → 7x/6x) would raise pre-dilution pipeline value from ~$1.90 to ~$3.80/sh — a swing of roughly +75% in the base case, well above the ±30% stability threshold, so treat the $2.29 base case as the center of a wide distribution, not a precise point estimate. ⚠️ Not investment advice. Not investment advice.

warning

⚠️ Terminated pharma partnership and stacked dilution overhang

Bristol-Myers Squibb ended its 2022 strategic collaboration with Century "without cause" as part of internal portfolio prioritization, effective March 12, 2025 — Century forfeited the relationship behind the original $150M upfront/equity package and over $3B in potential milestone ("biobucks") payments for the oncology iPSC-NK/gamma-delta T programs. The FY2025 revenue figure ($109.2M) is the one-time recognition of previously deferred BMS revenue triggered by that termination — not recurring or organic. Since then, Century raised $135M via a January 2026 private placement at $1.15/share (117.4M shares, plus 58.7M warrant shares that could bring in another ~$153M if exercised) and still has $131.6M available on an active ATM equity shelf. Combined, these three vectors represent a very large potential increase to the current 181.1M shares outstanding.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

29.0%

29.37M shares short, 96.2 days to cover. Very high for a name with this much cash — signals strong bear conviction on the IND outcome, but also latent squeeze risk on any positive catalyst.

🔴 Share dilution (1Y)

+109%

From ~86.6M weighted-average shares (FY2025) to 181.1M outstanding (Aug 3, 2026). Driven by the January 2026 $135M private placement (117.4M shares at $1.15) plus ongoing ATM sales.

🔴 Buyback

No buyback program — correctly so for a pre-revenue clinical-stage biotech; every dollar is earmarked for CNTY-813/CNTY-308 development and runway extension.

Short Interest — context

IPSC — 29.0%

29.0%

At nearly 30% of float and ~96 days to cover, this is an unusually crowded short for a stock with a fully-funded runway to 1Q29 — the bear thesis is almost certainly the IND/regulatory and translational risk on CNTY-813, not a solvency concern. No Form 4 activity beyond routine executive tax-withholding sales was found in the past 12 months (no red-flag insider selling).

$Financial analysis — FY2023–FY2026E

Cash & investments (6/30/26)

$197.2M

Guided runway into 1Q 2029

Net loss (Q2 2026)

−$34.6M

+6% vs. Q2 2025 (−$32.5M)

R&D spend (Q2 2026)

$19.6M

−27% YoY (cost discipline)

Shares outstanding

181.1M

+109% vs. FY25 weighted avg.

Item	FY2023	FY2024	FY2025	Guidance 2026E
Revenue	$2.2M	$6.6M	$109.2M (one-time)	~$0 (e)
R&D expense	$92.7M	$107.2M	$95.7M	~$74M (e)
G&A expense	$34.7M	$33.2M	$24.0M	~$25M (e)
Net income/(loss)	−$136.7M	−$126.6M	−$9.6M (masked)	~−$110M (e)
Cash & investments (EOY)	$261.8M	$220.1M	$117.1M	~$140M (e)

FY2025 revenue and net loss are distorted by the one-time recognition of deferred BMS collaboration revenue upon the March 12, 2025 contract termination — not organic growth. 2026E figures are extrapolated from H1 2026 actuals (company guidance is limited to "runway into 1Q 2029"), not formal management guidance, and are marked (e).

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025 (e)	Q1 2026	Q2 2026
Revenue ($M)	0.0	0.0	~0.0	0.0	0.0
Gross margin %	n.a.	n.a.	n.a.	n.a.	n.a.
Net loss ($M)	−32.5	−34.4	−19.3	−21.6	−34.6
Cash EOP ($M)	158.5	132.7	117.1	217.0	197.2

No cost-of-goods structure exists pre-commercialization, so gross margin is not applicable. Q4 2025 net loss is reconciled from FY2025 totals minus the three reported quarters (labeled (e)). The Q1 2026 cash jump reflects the $135M private placement closing in January 2026.

Financial position and sustainability

Runway remaining (to 1Q 2029)

~2.4 yrs

Potential dilution from warrants

+32% shares

Short interest vs. float

29.0%

account_tree

Business model — iPSC foundry, post-BMS pivot to autoimmune

From partnered oncology platform to proprietary autoimmune/T1D pivot

Century runs an induced pluripotent stem cell (iPSC) "foundry" that manufactures off-the-shelf, genetically engineered allogeneic cell therapies, differentiated by its Allo-Evasion immune-evasion technology (now in its 5th generation) designed to avoid rejection without chronic immunosuppression. Until March 2025, its lead economics ran through a 2022 Bristol-Myers Squibb collaboration on iPSC-derived NK and gamma-delta T cells for blood cancers (AML, multiple myeloma) — BMS terminated that deal "without cause" in a portfolio review, and Century subsequently axed its CD19 CAR-iNK oncology program (CNTY-101) and pivoted its resources to CNTY-813, a curative islet-cell replacement therapy for type 1 diabetes, alongside a newer proprietary CD19 CAR-iT program (CNTY-308) aimed at B-cell-mediated autoimmune disease.

CNTY-813 — T1D islet replacement Lead program · IND submission targeted Q4 2026 🟢 ramping iPSC-derived, immune-evaded pancreatic islet cells for type 1 diabetes. FDA pre-IND meeting reached alignment on the nonclinical package, manufacturing strategy and Phase 1/2 design. Initial clinical data expected 2H 2027. Vertex's zimislecel (VX-880) is years ahead in the same modality and is the key competitive benchmark. CNTY-308 — CD19 CAR-iT Wholly-owned · clinical entry targeted 2026 🟡 to be proven CD4+/CD8+ αβ CAR-iT cell therapy targeting CD19 for B-cell-mediated diseases (the same "immune reset" thesis behind the broader autoimmune CAR-T wave). Earlier stage than CNTY-813; no confirmed IND date disclosed yet. Legacy oncology / CARAMEL IST Deprioritized post-BMS termination 🔴 in stalled Remnant of the pre-2025 oncology pipeline (CD19 CAR-iNK, ELiPSE-1/CARAMEL investigator-sponsored trial). CNTY-101 was discontinued; updated preliminary CARAMEL data is still expected in 2026 but is no longer strategically central.

gavel

Legal, regulatory and risk analysis

Terminated BMS partnership

High

Lost the only validated big-pharma relationship (forfeited $150M upfront/equity package plus >$3B in potential biobucks) effective March 12, 2025. Century currently has zero active pharma partner or non-dilutive capital source.

Stacked dilution overhang

High

58.7M outstanding warrant shares (+32% of current count) plus $131.6M of untapped ATM capacity. Both are likely to be used opportunistically as cash needs arise before self-sufficiency, well before 1Q 2029.

Regulatory / translational risk

High

CNTY-813 has not yet filed an IND; nonclinical-to-clinical translation risk for a first-in-human iPSC-derived islet product is substantial even with FDA pre-IND alignment on the data package.

Competitive risk vs. Vertex

Moderate

Vertex's zimislecel (stem-cell-derived islet therapy) is years ahead in clinical development in the same indication; Century's differentiation rests on avoiding chronic immunosuppression, unproven in humans for this program.

Runway covers both catalysts

Positive

$197.2M cash and investments with guided runway into 1Q 2029 comfortably spans the Q4 2026 IND filing and the 2H 2027 initial clinical data readout.

Clean balance sheet

Positive

No interest-bearing debt; the $54.7M in total liabilities is standard operating (accrued expenses, lease, payables), not financial leverage.

Elevated short interest

Moderate

29.0% of float short, 96 days to cover — an unusually crowded short for a fully-funded name, adding volatility risk in both directions around the IND catalyst.

Insider activity / governance

Low

No class actions, SEC investigations, or short-seller reports found. Form 4 filings over the past 12 months show only routine executive tax-withholding sales — no material insider selling flagged.

article

SWOT analysis

Strengths

+Proprietary iPSC foundry and Allo-Evasion 5.0 immune-evasion platform
+Cash runway into 1Q 2029 covers both the IND filing and initial clinical data readout
+No debt; balance sheet is clean aside from standard operating liabilities
+FDA alignment already reached on the CNTY-813 nonclinical package and Phase 1/2 design
+New board addition (Joseph Truitt) brings a track record of biotech M&A exits and BD experience

Weaknesses

−Pre-revenue, pre-IND stage — the entire lead program is unproven in humans
−Share count up ~109% in under 18 months; two more dilution vectors (warrants, ATM) still open
−Lost its only validated pharma partner (BMS) with no replacement signed
−Quarterly burn run-rate (~$25-35M) implies FY2026 cash use of well over $100M

Opportunities

→T1D curative cell therapy addresses a ~1.6M-patient U.S. population with high unmet need
→Autoimmune CD19 CAR-T/CAR-iT (CNTY-308) is one of the best-funded thematic areas in biotech right now
→A new strategic pharma partnership would bring non-dilutive capital and third-party validation

Threats

!Vertex's zimislecel is years ahead in the same stem-cell-islet modality for T1D
!Crowded, well-capitalized allogeneic cell-therapy competitive set (Sana, Fate, Allogene)
!Further dilutive financing is likely before Century reaches any inflection point
!Binary regulatory/clinical risk concentrated in a single lead program

article

Summary by assessment area

💰 Financial Risk — Moderate

Cash covers runway to 1Q29, zero debt
But holders already diluted ~2x since early 2025, with more overhang open

🧪 Execution / Clinical Risk — High

Pre-IND lead program, first-in-modality translational risk
Vertex is years ahead in the same T1D approach

⚖️ Governance / Market Risk — Moderate

No litigation or SEC flags; only routine insider activity
29% short interest signals strong bear conviction; new board hire adds BD experience

2026-11-12 earnings

Q3 2026 Earnings Release

short-term Impact: Medium Direction: Neutral

Date estimated from the Q3 2025 reporting pattern. Watch for updated cash burn, ATM usage disclosure, and any CNTY-813 IND-readiness commentary ahead of year-end.

2026-11-30 product

CNTY-308 First Patient Dosed

medium-term Impact: High Direction: Binary

Company guidance points to clinical entry in 2026; date is a conservative estimate. Confirms the second pipeline leg beyond CNTY-813 is real and de-risks the single-program concentration.

2026-12-31 regulatory

CNTY-813 IND Submission (Q4 2026 target)

medium-term Impact: High Direction: Binary

The single most important near-term catalyst. A clean filing (no clinical hold) validates the FDA pre-IND alignment and is the gating event for the entire investment thesis.

2026-12-31 product

CARAMEL IST Updated Preliminary Data

medium-term Impact: Medium Direction: Neutral

Legacy oncology signal, no longer strategically central after the pivot, but still a free look at platform durability data.

2026-12-31 capital_markets

ATM Shelf Utilization / Potential New Equity Raise

medium-term Impact: Medium Direction: Bearish

$131.6M remains available on the active $150M ATM shelf ($18.4M already sold). Continued opportunistic sales, especially into price strength around the IND filing, are a realistic ongoing overhang.

2027-01-08 capital_markets

Private Placement Warrant Exercise Window

long-term Impact: Medium Direction: Neutral

58.7M warrant shares from the January 2026 private placement could bring in ~$153M of additional capital if exercised, at the cost of further dilution — a genuine two-sided catalyst to track over the following year.

2027-06-30 product

CNTY-813 Initial Clinical Data (Phase 1/2)

long-term Impact: High Direction: Binary

Guided for 2H 2027. The true value-defining event: human proof-of-concept for immune-evaded islet replacement without chronic immunosuppression.

2027-03-31 partnership

Potential New Strategic Pharma Partnership

long-term Impact: Medium Direction: Bullish

Speculative but plausible: the new board addition (Joseph Truitt, a BD/M&A-oriented director) raises the odds of a replacement partnership that would bring non-dilutive capital and validation.

{ "verdict_label": {"it": "Giudizio: Moderatamente Attraente — biotech pre-IND, binario", "en": "Verdict: Moderately Attractive — binary, pre-IND biotech"}, "verdict_text": {"it": "Century ha perso il suo unico partner farmaceutico (BMS, marzo 2025) e ha virato su CNTY-813 per il diabete T1D. La cassa copre fino al 1Q29, ma la diluizione e' gia' raddoppiata le azioni in circolazione.", "en": "Century lost its only pharma partner (BMS, March 2025) and pivoted to CNTY-813 for type 1 diabetes. Cash covers into 1Q29, but dilution has already roughly doubled shares outstanding."}, "bull_points": [ {"it": "Cassa $197M, runway fino al 1Q29: copre sia il filing IND sia i dati clinici", "en": "$197M cash, runway into 1Q29: covers both the IND filing and clinical data"}, {"it": "Nessun debito, bilancio pulito, allineamento FDA gia' raggiunto sul programma T1D", "en": "No debt, clean balance sheet, FDA alignment already reached on the T1D program"}, {"it": "Nuovo board member con track record di M&A/exit rafforza governance e BD", "en": "New board member with an M&A/exit track record strengthens governance and BD"} ], "bear_points": [ {"it": "Azioni in circolazione +109% in 18 mesi, altri 58.7M warrant e $131.6M di ATM ancora aperti", "en": "Shares outstanding +109% in 18 months, another 58.7M warrants and $131.6M of ATM still open"}, {"it": "Ricavi FY25 di $109M sono un artefatto contabile una tantum, non business ricorrente", "en": "FY25 revenue of $109M is a one-time accounting artifact, not recurring business"}, {"it": "Vertex e' anni avanti nella stessa modalita' di cellule staminali per il T1D", "en": "Vertex is years ahead in the same stem-cell modality for T1D"} ], "risks": [ {"it": "IND di CNTY-813 non ancora depositato: rischio regolatorio binario concentrato", "en": "CNTY-813 IND not yet filed: concentrated binary regulatory risk"}, {"it": "Diluizione strutturale in corso su tre fronti (warrant, ATM, potenziali nuovi round)", "en": "Structural dilution underway on three fronts (warrants, ATM, potential new rounds)"}, {"it": "Short interest al 29% del flottante: alta convinzione ribassista sul mercato", "en": "Short interest at 29% of float: strong bearish conviction in the market"} ] }

Sources & Disclaimer

Sources: Century Therapeutics Q2 2026 10-Q (SEC EDGAR), FY2025/FY2024/FY2023 and Q1-Q3 2025/Q1 2026 earnings releases (GlobeNewswire/BioSpace/investors.centurytx.com), January 2026 private placement and March 2026 ATM shelf filings (SEC EDGAR/StockTitan), BMS termination disclosures (Dec 2024/Fierce Biotech), H.C. Wainwright analyst note (Apr 21, 2026), StockAnalysis.com, Fintel, Investing.com. Market data as of September 10-11, 2026: IPSC ~$2.00, market cap ~$362M, 52W: $0.435–$3.04, 181,075,321 shares outstanding (Aug 3, 2026). Short interest: 29.0%. This document is for informational purposes only and does not constitute financial or investment advice.